Professional Beauty - Botox gets UK approval for use on crow's feet

Botox gets UK approval for use on crow's feet


9 January 2014
Botox gets UK approval for use on crow's feet

Facial injectable Botox has been approved for use on crow's feet by the Medicines and Healthcare products Regulatory Agency MHRA, which governs its use in the UK.

Allergan, the manufacturer of the injectable drug, received a licence for this new indication. The decision follows a similar licence for use in the US, granted in September by the Food & Drug Administration. 

The new licence approves the drug for "temporary improvement in the appearance of moderate to severe lateral canthal lines (crow’s feet) seen at maximum smile, either alone or when treated at the same time as glabellar (or frown) lines seen at maximum frown, in adult patients where these facial lines have an important psychological impact." 

The authorisation is specific to Allergan’s botulinum toxin type A product and was granted based on the results of the brand's  clinical trials  for crow’s feet involving more than 1,350 patients. 

Botox has long been used to treat glabellar lines alone but this licence marks the first time it can legally be used on this new area of the face.

Read more about:
Business, Medical Aesthetics
Related Articles
Professional Beauty Magazine
June 2015 cover      

Packed with valuable news and business advice. Subscribe today to receive monthly print issues for only £37 per year: Subscribe

Or sign up for a digital-only subscription to view every issue on your tablet, smartphone or desktop computer for just £4.99 a year: Subscribe